title: FEIBA: a prohemostatic agent.
abstract: Factor eight inhibitor bypassing activity (FEIBA), Anti-Inhibitor Coagulation Complex has been used for over 30 years in hemophiliac patients with inhibitors. The history of its use is reviewed here, including issues related to thrombosis, efficacy, and comparison to alternative bypassing agents. The need for surrogate assays to monitor effective hemostasis with the use of FEIBA remains.
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029-6574, USA. caroline.cromwell@mssm.edu
authors.forename: Caroline
authors.initials: C
authors.lastname: Cromwell
authors.forename: Louis M
authors.initials: LM
authors.lastname: Aledort
mesh_terms: D001779:Blood Coagulation Factors / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D013927:Thrombosis / Q000188:drug therapy
chemical_list: D001779:Blood Coagulation Factors; D006490:Hemostatics; C065655:anti-inhibitor coagulant complex